Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Cervical Cancer Prevention in El Salvador: Gains to Date and Challenges for the Future

Version 1 : Received: 21 May 2022 / Approved: 23 May 2022 / Online: 23 May 2022 (05:15:50 CEST)

A peer-reviewed article of this Preprint also exists.

Alfaro, K.; Soler, M.; Maza, M.; Flores, M.; López, L.; Rauda, J.C.; Chacón, A.; Erazo, P.; Villatoro, N.; Mumenthaler, E.; Masch, R.; Conzuelo, G.; Felix, J.C.; Cremer, M. Cervical Cancer Prevention in El Salvador: Gains to Date and Challenges for the Future. Cancers 2022, 14, 2776. Alfaro, K.; Soler, M.; Maza, M.; Flores, M.; López, L.; Rauda, J.C.; Chacón, A.; Erazo, P.; Villatoro, N.; Mumenthaler, E.; Masch, R.; Conzuelo, G.; Felix, J.C.; Cremer, M. Cervical Cancer Prevention in El Salvador: Gains to Date and Challenges for the Future. Cancers 2022, 14, 2776.

Abstract

Cervical cancer is preventable through vaccination, early detection, and treatment of precancerous lesions. However, global inequalities mean that the disease remains a leading cause of cancer death around the world, with over 80% of new cases and 90% of deaths occurring in low and middle-income countries (LMICs). In El Salvador, joint efforts between the Ministry of Health (MoH) and the non-profit organization Basic Health International (BHI) have been in place since 2008 with the goal of reducing the country’s disease burden. While the World Health Organization’s (WHO) call to action to eliminate cervical cancer provided worldwide momentum to implement new public health initiatives, the COVID-19 pandemic disrupted ongoing programs and jeopardized plans for the future. The purpose of this manuscript is to describe the progress that El Salvador has achieved in improving cervical cancer prevention, the impact of the pandemic on current strategies, and potential solutions that can help the country meet the WHO’s strategic targets by 2030 to accelerate the elimination of cervical cancer.

Keywords

El Salvador; Cervical cancer; Human papilloma virus (HPV); screen-and-treat; cervical precancer; HPV vaccine

Subject

Medicine and Pharmacology, Obstetrics and Gynaecology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.